**Opioid Settlement Funds**

Request for Funding Proposals MAC Template

**Overview**

\_\_\_\_\_\_\_ County invites organizations or groups addressing opioid prevention, harm reduction, treatment and recovery to apply for funding to support development, implementation, enhancement or expansion of programs. This includes programs addressing substance use disorders, polysubstance use and co-occurring mental health and substance use disorders. While the selection process will utilize a competitive Request for Proposals (RFP) process, the number of awards will be dependent on the amount of funds available for annual allocation. The amount of funds available will differ annually and proposals will be accepted annually beginning in \_\_\_\_\_\_\_\_\_ (month).

**Background**

In 2021, a $26 billion nationwide settlement was reached to resolve all Opioids litigation brought by states and local political subdivisions against the three largest pharmaceutical distributors: McKesson, Cardinal Health and AmerisourceBergen (“Distributors”), and manufacturer Janssen Pharmaceuticals, Inc. and its parent company Johnson & Johnson (collectively, “J&J”). In 2022, additional settlements with pharmacies and manufacturers were announced, including CVS, Walmart, Walgreens, Allergan and Teva. In 2023, a settlement with Kroger was also reached.

Fifty percent (50%) of the settlement amounts will be sent directly to county and local governments. Payments for all settlements will be received separately. Eighty-five percent (85%) of funds must be used for opioid remediation, with seventy percent (70%) being used for future opioid remediation. Exhibit E of the settlements provides a non-exhaustive list of expenditures that qualify as being paid for Opioid Remediation.

Michigan can also expect additional funds received through companies Purdue Pharma, Mallinckrodt PLC and Endo, which are pursuing bankruptcy plans that include funding opioid abatement trusts.

*Currently, \_\_\_\_\_\_\_\_\_ County has received \_\_\_\_\_\_\_ dollars from opioid settlements. Due to funding amounts changing annually, \_\_\_\_\_\_\_\_\_ County will, on average, have \_\_\_\_ dollars available each year for opioid remediation activities. The number of payments/length of time for each settlement will also differ.*

**Goal**

The goal of this opportunity is to serve \_\_\_\_\_\_\_ County through development, implementation, enhancement or expansion of evidence-based strategies or promising practices to prevent and address the adverse impacts of the drug overdose epidemic.

**Eligibility**

Organizations or groups addressing opioid prevention, harm reduction, treatment and recovery are eligible for funding to support development, implementation, enhancement or expansion of programs. This includes programs addressing substance use disorders, polysubstance use and co-occurring mental health and substance use disorders.

* Add county specific eligibility requirements (organization status, location, financial and legal requirements, etc.)

**Availability of Funds**

The number of awards will be dependent on the amount of funds available for annual allocation. The amount of funds available will differ annually. Proposals will be accepted annually between \_\_\_\_\_\_\_\_\_\_ (start date) and \_\_\_\_\_\_\_\_\_\_ (end date).

The period of funding will be from \_\_\_\_\_\_\_\_\_\_ (start date) through \_\_\_\_\_\_\_\_\_\_ (end date).

**Requirements**

Proposal Priorities

* Utilize funds to serve those in \_\_\_\_\_\_\_ County
* Focus on individuals and communities most profoundly impacted by opioid use disorder (OUD) and co-occurring substance use disorder/mental health conditions (SUD/MH)

Organizations awarded funded are required to:

* Ensure utilization of funds supplements, rather than supplants, existing funding
* Ensure all funds are used in alignment with Exhibit E and the definition of opioid remediation
* Ensure indirect costs do not exceed \_\_\_ percent (\_\_\_%)
* Provide data on program outputs, outcomes, impact and effectiveness, following agreed upon metrics with \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ (county team)
* Complete required \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ (monthly/quarterly) and annual reports
* Add county specific requirements (submission of specific documentation, timeline, etc.)

Reporting Requirements

* Organizations should provide \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ (monthly/quarterly) by \_\_\_\_\_\_\_\_\_\_ (date of month) to \_\_\_\_\_\_\_\_\_\_ (county contact) progress reports outlining the following:
  + Staff working on the project
  + Community partners involved with the project
  + Challenges and barriers experienced within the associated timeframe
  + Successes experienced within the associated timeframe
  + Anticipated next steps
* Annual report to be provided at project close by \_\_\_\_\_\_\_\_\_\_ (date) to \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ (county contact name) to include
  + Metrics to gauge outputs, outcomes, impact and effectiveness as determined through scope of work and agreed upon with \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ (county team)

**Allowable Uses of Funds & Funding Restrictions**

Specific to the J&J, Distributor, CVS, Teva, Allergan and Walmart settlements, funds must be spent on opioid remediation. Opioid Remediation is defined as,[[1]](#footnote-1)

Care, treatment, and other programs and expenditures (including reimbursement for past such programs or expenditures except where this Agreement restricts the use of funds solely to future Opioid Remediation) designed to (1) address the misuse and abuse of opioid products, (2) treat or mitigate opioid use or related disorders, or (3) mitigate other alleged effects of, including on those injured as a result of, the opioid epidemic.

Activities must meet the definition of opioid remediation, be evidence-based strategies[[2]](#footnote-2)[[3]](#footnote-3) or promising practices and align with allowable uses outlined by [Exhibit E](https://www.attorneygeneral.gov/wp-content/uploads/2021/12/Exhibit-E-Final-Distributor-Settlement-Agreement-8-11-21.pdf).[[4]](#footnote-4) These strategies include:

1. **Core Strategies**

* Naloxone or other FDA-approved drug to reverse opioid overdoses
* Medication-assisted Treatment (MAT) distribution and other opioid-related treatment
* Address the needs of pregnant and postpartum women
* Expanding treatment for Neonatal Abstinence Syndrome (NAS)
* Expansion of warm hand-off programs and recovery services
* Treatment for incarcerated population
* Prevention programs
* Expanding syringe service programs
* Evidence-based data collection and research analyzing the effectiveness of the abatement strategies within the state

1. **Approved Uses - Prevention**

* Prevent over-prescribing and ensure appropriate prescribing and dispensing of opioids
* Prevent misuse of opioids
* Prevent overdose deaths and other harms (harm reduction)

1. **Approved Uses - Treatment**

* Treat Opioid Use Disorder (OUD)
* Support people in treatment and recovery
* Connect people who need help to the help they need (connections to care)
* Address the needs of criminal justice-involved persons
* Address the needs of pregnant or parenting women and their families, including babies with NAS

1. **Approved Uses – Other Strategies** 
   * Supporting first responders
   * Leadership, planning and coordination
   * Training
   * Research

Indirect costs may not exceed \_\_\_\_\_\_\_\_ percent (\_\_\_%) of funds.

**Selection and Award Process**

All proposals submitted should include the completed Request for Proposals document below, resume or biography of the project director, any optional documents and the attached budget template. Proposals will be reviewed and scored by \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ (county team).

Proposals are due to \_\_\_\_\_\_\_\_\_\_ (county contact name) at \_\_\_\_\_\_\_\_\_\_ (county contact email) by \_\_\_\_\_\_\_\_\_\_ (date). Notice of award is expected to occur by \_\_\_\_\_\_\_\_\_\_ (date). Following the notice of award, organizations will meet with \_\_\_\_\_\_\_\_\_\_ (county contact name) to discuss the contract process and specific metrics for the project identified. The period of funding will be \_\_\_\_\_\_\_\_\_\_ (start date) through \_\_\_\_\_\_\_\_\_\_ (end date).

* Add county priorities (specific populations, etc.)
* Add county specific award information (type of contract, requirements, etc.)

**Scoring criteria and weighting**

|  |  |  |  |
| --- | --- | --- | --- |
| **CRITERIA SCORES** | | | **WEIGHT** |
| 1. Adherence to RFP Instructions | | | 0.05 |
| 2. Organization Information & Description | | | 0.05 |
| 3. Project Description | | | 0.25 |
| 4. Population Served & Geographic Area | | | 0.05 |
| 5. Data to Support Need | | | 0.05 |
| 6. Timeline | | | 0.05 |
| 7. Scope of Work | | | 0.25 |
| 8. Measures of Success |  |  | 0.10 |
| 9. Sustainability |  |  | 0.10 |
| 10. Budget | | | 0.05 |
| **Total Score** | |  | 1.00 |

With questions related to this funding opportunity, please contact \_\_\_\_\_\_\_\_\_\_ (county contact name) at \_\_\_\_\_\_\_\_\_\_ (county contact email).

**Request for Proposals**

\_\_\_\_\_\_\_ County Opioid Settlement Funds – FY \_\_

|  |  |
| --- | --- |
| **RFP Posted** | \_\_\_\_\_\_\_\_\_\_ (date) |
| **Proposals Due** | \_\_\_\_\_\_\_\_\_\_ (date) |
| **Anticipated Notice of Award** | \_\_\_\_\_\_\_\_\_\_ (date) |
| **Anticipated Performance Period** | \_\_\_\_\_\_\_\_\_\_ (start date - end date) |
| **Questions to** | \_\_\_\_\_\_\_\_\_\_ (county contact email) |

**To Be Completed by Organization Submitting Proposal:**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **1. Organization Information** | | | | | |
| **Organization Name** | |  | | | |
| **Street Address** | |  | | | |
| **Email Address** | |  | | | |
| **Phone Number** | |  | | | |
| **Name of Project Director** | |  | | | |
| **Title of Project Director** | |  | | | |
| **Name of Authorized Representative** | |  | | | |
| **Title of Authorized Representative** | |  | | | |
| **Signature of Authorized Representative** | |  | | | |
| **Date** | |  | | | |
| **2. Organization Description** | | | | | |
| **3. Project Description Including Project Objectives** | | | | | |
| **4. Populations Served/Target Population and Geographic Area Served** | | | | | |
| **5. Data to Support Need for Project** | | | | | |
| **6. Project Timeline Overview** | | | | | |
| **7. Scope of Work** | | | | | |
| **Activity** | **Outputs** | | | **Outcomes** | **Timeline** |
|  |  | | |  |  |
|  |  | | |  |  |
|  |  | | |  |  |
|  |  | | |  |  |
|  |  | | |  |  |
|  |  | | |  |  |
|  |  | | |  |  |
| **8. Success – How will success be measured?** | | | | | |
| **9. Sustainability – How will the project be sustained after funding cycle?** | | | | | |
| **10. Budget – Total amount requested** | | | **$** | | |
| **11. Budget Narrative – How will funds be used to meet project goals?** | | | | | |
| **12. New or Existing Project – Check one** | | | \_\_ - Existing \_\_ - New | | |
| **12.a. If existing, how many unique individuals are served annually by the current project?** | | |  | | |
| **12.b. If new, is the project evidence-based or based on promising practices? (Check one and provide link to information on evidence base)** | | | \_\_ - Yes \_\_ - No  Link: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | | |
| **13. Attachments – Supporting Documents** | | | * Resume and/or biography of project director * Completed budget template (provided) * Letters of support from partner organizations (optional) * Materials demonstrating experience, organizational impact and/or commitment to addressing the drug overdose epidemic (optional) | | |

**Resources**

* Principles for Spending
  + [Principles for the Use of Funds From the Opioid Litigation](https://opioidprinciples.jhsph.edu/wp-content/uploads/2022/02/Opioid-Principles-Doc.pdf)
* Evidence-Based Strategies and Promising Practices
  + [Evidence Based Strategies for Abatement of Harms from the Opioid Epidemic](https://www.lac.org/assets/files/TheOpioidEbatement-v3.pdf)
  + [Evidence-Based Strategies for Preventing Opioid Overdose: What's Working in the United States](https://www.cdc.gov/drugoverdose/pdf/pubs/2018-evidence-based-strategies.pdf)
* Local data
  + [Michigan Overdose Data to Action Dashboard](https://www.michigan.gov/opioids/category-data)
    - Data on overdose deaths, emergency department visits and emergency medical services (EMS) calls and Substance Use Vulnerability Index
  + [Michigan Department of Health and Human Services Opioids Webpage - EMS Responses](https://www.michigan.gov/opioids/category-data)
    - “Public Use Dataset EMS Responses to Probable Opioid Overdose”, found under “Overdose Reports”
  + [Michigan Substance Use Disorder Data Repository (SUDDR)](https://mi-suddr.com/) and [Data Visualizations](https://tbdsolutions.shinyapps.io/misuddr-app/)
    - Suspected fatal overdoses and emergency medical services naloxone administration data
  + [University of Michigan Injury Prevention Center System for Opioid Overdose Surveillance (SOS)](https://systemforoverdosesurveillance.com/)
    - County-level data on overdose deaths, emergency department visits and emergency medical services (EMS) calls
  + [Overdose Detection Mapping Application Program (ODMAP)](https://www.odmap.org:4443/Content/docs/training/general-info/ODMAP-Overview.pdf)
    - Near real-time tracking of fatal and non-fatal overdoses and naloxone administration by public health and public safety
  + [Wayne State University’s School of Social Work Center for Behavioral Health and Justice Dashboard](https://behaviorhealthjustice.wayne.edu/news/new-data-dashboard-gives-michiganders-access-to-data-in-one-place-for-the-first-time-42141)
    - Customizable dashboard that shows multiple topics including, behavioral health, public health, criminal justice, housing, demographic and other data
  + Data and information may also be accessed through local communities within health departments, prevention coalitions, harm reduction providers, behavioral health providers, recovery support providers and other groups.

1. <https://nationalopioidsettlement.com/> [↑](#footnote-ref-1)
2. <https://www.lac.org/assets/files/TheOpioidEbatement-v3.pdf> [↑](#footnote-ref-2)
3. <https://www.cdc.gov/drugoverdose/pdf/pubs/2018-evidence-based-strategies.pdf> [↑](#footnote-ref-3)
4. <https://www.attorneygeneral.gov/wp-content/uploads/2021/12/Exhibit-E-Final-Distributor-Settlement-Agreement-8-11-21.pdf> [↑](#footnote-ref-4)